The second Trump administration is expected to revisit and pursue unfinished pharmacy regulation priorities from its first term. These include drug price transparency, promoting biosimilars, and expanding pharmacists' scope of practice. The administration will likely seek to advance these issues in alignment with conservative think tanks and statehouses, with potential impacts on drug pricing, vaccine policies, and pharmacy services. Click here for article.
The Trump administration may strengthen drug price transparency, including enforcing the Transparency in Coverage (TiC) Rule and improving consumer access to drug pricing.
The administration is likely to push for increased availability of biosimilars, promoting competition and lower prices for biologic drugs.
If RFK Jr. is confirmed as Health and Human Services Secretary, his stance on vaccine safety may influence pharmacy vaccine service delivery and reimbursement policies.
Expanding the scope of practice for pharmacists, including reimbursement for new services, could gain momentum with new legislative support at the federal and state levels.
Comments